Expression of CD147 is associated with prostate cancer progression

Abstract

Novel molecular markers that are associated with prostate cancer (PCa) progression will provide valuable information in the diagnosis and treatment of the disease. Extracellular matrix metalloproteinase inducer (CD147) has been demonstrated to be involved in tumor invasion, metastasis, growth and survival. In our study, we examined whether the expression of CD147 can be used as a prognostic marker for predicting PCa progression. Tissue samples from 240 patients who received radical prostatectomy for PCa were obtained. CD147 expression in these samples was evaluated using immunohistochemical staining with a monoclonal antibody specifically against CD147. Increased expression of CD147 was correlated with higher Gleason scores (GS), positive surgical margin, prostate-specific antigen (PSA) failure, metastasis and reduced overall survival. Both univariate Cox regression analysis and multivariate analysis including competing biological variables demonstrated that increased CD147 expression was associated with increased risk for reduced PSA failure-free, metastasis-free and overall survival. Kaplan-Meier survival curves showed that the CD147 overexpression was a significant predictor for the PSA failurefree, metastasis-free and the overall survival in both pT2 and pT3 PCa patients. More significantly, higher expression of CD147 can serve as an independent prognostic predictor for PSA failure-free survival in PCa patients when they are stratified by GS. Our study results demonstrate the involvement of CD147 in PCa progression and suggest its potential role as an independent predictor of biochemical recurrence, development of metastasis and reduced overall survival in PCa.Prostate cancer (PCa) is one of the most common cancers and the second leading cause of cancer death in men. 1 Although patients with localized PCa can often be successfully treated with radical prostatectomy or radiation therapy, PCa deaths are usually the results of hormone refractory and metastatic disease. It is often difficult to identify patients who will progress, recur and require additional treatments. PCa prognosis varies significantly in patients according to clinical stage and pathological grade. More sensitive PCa novel molecular markers that are associated with biological aggressiveness and providing valuable information in the diagnosis and treatment of the disease are of particular importance. Currently, effective treatment of metastatic disease is one of the major therapeutic challenges in PCa treatment. 2 In recent years, many studies have focused on identifying nomograms to include various prognostic parameters to predict PCa outcome. [3][4][5] PCa cells with high-and low-metastatic potential vary in their biological properties, such as proliferation, adhesiveness, invasiveness and motility. These variations are the results of both germ line variation between individuals and somatic alterations of genes and gene expressions in cancer

Survival Outcome and EMT Suppression Mediated by a Lectin Domain Interaction of Endo180 and CD147

“…The findings of this study also confirm that, similar to the upregulation of CD147 (5,16), the increased expression of Endo180 is correlated with increasing Gleason score (Fig. 1B) and has prognostic value as an independent predictor of overall survival (Fig.…”

Aberrant hypomethylation-mediated CD147 overexpression promotes aggressive tumor progression in human prostate cancer

“…As shown in Fig. 1, both CD147 mRNA and protein were highly expressed in PCa cell lines compared to non-tumorigenic benign human prostatic epithelial cell lines (all P<0.01), which were consistent with our previous data in human PCa and non-cancerous prostate tissues (21,24,25).…”

“…Especially in PCa, Wang et al (20) found that CD147 downregulation by RNAi technology could decrease the invasive capability of the PCa cells; data of our research group (21) and Madigan et al (22) both showed that CD147 could regulate MMPs and was involved in PCa progression. Hao et al (23) also reported that CD147 expression may be correlated with drug resistance during PCa metastasis and may be a useful potential therapeutic target in advanced disease; our research group further identified the potential role of CD147 as an independent predictor of biochemical recurrence, development of metastasis and reduced overall survival in PCa (24,25). However, the mechanisms that result in the aberrant expression of CD147 in PCa are not fully elucidated.…”

Extracellular matrix metalloproteinase inducer and matrix metalloproteinase-2 overexpression is associated with loss of hormone receptor expression and poor prognosis in endometrial cancer

“…Tissue sections were independently evaluated by two gynecological pathologists who were blinded to the identity and clinical status of each patient. The immunohistochemical expression was semi-quantitatively measured, as described by Zhong et al (9), by assessing the percentage and staining intensity of stained tumor cells. Samples were scored from 0-3 based on the percentage of cells exhibiting positive staining as follows: 0 points, 0-5%; 1 point, 6-50%; 2 points, 51-75%; and 3 points, >75%.…”

“…MMP-2 has been extensively studied and is particularly important in cancer invasion and metastasis. Studies have shown that CD147 is overexpressed in a number of human cancer types, including gastric carcinoma, breast cancer, prostate cancer and cervical cancer (8)(9)(10), and the overexpression of CD147 is associated with an aggressive cancer phenotype and poor prognosis for the patient. Additionally, the overexpression of CD147 in malignant cells is associated with metastatic and invasive ability, and sensitivity to growth inhibitory signals (11).…”